Disease‐Specific Determinants of Cardiovascular Nanomedicine: Mechanisms, Limitations, and Translational Opportunities
Cardiovascular Therapeutics · 2026-01 · 2026 (1)
DOI: 10.1155/cdr/8263083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 06.11.2026. Verfasst von Boopalan Sivanathan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Pharmacology and Toxicology, School of Medicine, West Virginia University, Morgantown, West Virginia, USA, wvu.edu. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Nanomedicine, Translational Research, Biomedical, Cardiovascular Agents. Die Arbeit nennt 267 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NHLBI NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, yet most therapies lack cardiovascular tissue‐ and cell‐specificity, limiting efficacy and increasing off‐target toxicity. Nanoparticle‐based drug delivery systems offer opportunities to enhance myocardial targeting, improve pharmacokinetics, and enable controlled or stimuli‐responsive release. However, despite extensive preclinical success, clinical translation of cardiovascular nanomedicine remains limited. A major gap is the insufficient integration of disease‐specific cardiac biology into nanoparticle design. Here, we propose that the success of cardiovascular nanomedicine depends on integrating nanoparticle physicochemical properties and disease‐specific microenvironmental conditions, including inflammation, vascular permeability, fibrosis, immune activation, and intracellular stress signaling. We provide a mechanistic and disease‐contextual framework to guide nanoparticle design across major cardiovascular conditions, including myocardial infarction, heart failure, atherosclerosis, and doxorubicin‐induced cardiotoxicity, while distinguishing cardiomyocyte‐directed delivery from vascular‐, immune‐cell‐, and stromal‐targeted strategies. Here, we critically evaluate current targeting strategies and major translation barriers associated with cell‐specific delivery, off‐target organ accumulation, preclinical models, manufacturing and scalability, and long‐term safety. This review shifts the paradigm from material‐centric to biology‐guided nanoparticle design and outlines actionable strategies to advance cardiovascular precision therapeutics toward clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Pharmacology and Toxicology, School of Medicine, West Virginia University, Morgantown, West Virginia, USA, wvu.edu.
- Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia, USA, wvu.edu.
ORCID-Profile: Boopalan Sivanathan, Sharan Bobbala, Sundararajan Venkatesh
Förderung
- NIGMS NIH HHS
- NHLBI NIH HHS
- National Institute of General Medical Sciences
- National Heart, Lung, and Blood Institute
Zitieren
APA
Sivanathan, B., Bobbala, S., & Venkatesh, S. (2026). Disease‐Specific Determinants of Cardiovascular Nanomedicine: Mechanisms, Limitations, and Translational Opportunities. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/8263083
Vancouver
Sivanathan B, Bobbala S, Venkatesh S. Disease‐Specific Determinants of Cardiovascular Nanomedicine: Mechanisms, Limitations, and Translational Opportunities. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/8263083
BibTeX
@article{Sivanathan2026,
author = {Sivanathan, Boopalan and Bobbala, Sharan and Venkatesh, Sundararajan},
title = {Disease‐Specific Determinants of Cardiovascular Nanomedicine: Mechanisms, Limitations, and Translational Opportunities},
journal = {Cardiovascular Therapeutics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cdr/8263083}
}
EUVIMED